September 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in September 2022 for investigational products in development.
Alopecia
FDA to Review Ritlecitinib for Alopecia Areata
Ritlecitinib is the first in a new class of oral highly selective kinase inhibitors.
Study Investigating Oral JAK Inhibitor for Alopecia Areata Meets Endpoint
CTP-543 is an investigational oral selective inhibitor of JAK1 and JAK2.
MPR Weekly Dose Podcast #120
FDA panel vote on COVID-19 vaccines for young children; new drug approved to treat alopecia; Paxlovid tested in standard risk individuals.
Olumiant Approved for Severe Alopecia Areata
The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.
Significant Hair Regrowth Observed With Investigational JAK Inhibitor in Alopecia Areata Trial
The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.
Treatments Explored for Moderate-to-Severe Alopecia Areata
Improvement in lesional scalp transcriptome toward nonlesional profile seen at week 24 for both ritlecitinib, brepocitinib
Taxane-Containing Chemo Associated With Persistent Alopecia
However, many patients experience improvements in hair density with standard alopecia treatments
Second Alopecia Areata Trial Demonstrates Hair Regrowth With Baricitinib
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.
